Changes of Visual Field Defects After IAT for CRAO

Status Completed

Clinical Trial Summary

Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization may reduce the complications such as intracranial and systemic hemorrhage. The residual visual field is significant for patients with CRAO who have poor central visual acuity. Thus, it is clinically significant to study the changes in visual fields in eyes with CRAO.

Clinical Trial Description

Central retinal artery occlusion (CRAO) is an ophthalmic emergency which leads to devastating visual function defects and poor prognosis. Though traditional conservative treatments are widely used, none of them is proved to be effective. The respective responses of brain and retinal tissues to acute ischemia share many features is the rationale for therapeutic thrombolysis in CRAO. Intravenous thrombolysis (IVT) has been a therapeutic choice for CRAO since the 1960s, and in the United States, tPA is currently administered in 5.8% of patients admitted with CRAO. A number of meta-analyses and observational studies indicate intravenous thrombolysis to be beneficial in CRAO. Selective intra-arterial thrombolysis (IAT) introducing rt-PA directly into the ophthalmic circulation by super-selective microcatheterization which has the advantage of reducing the dose of rt-PA reaching the systemic circulation. It is clinically significant to study the changes in visual fields in eyes with CRAO. The short-term temporal changes (≤7-day) of VFDs and the adverse reactions in eyes with CRAO after IAT were investigated to assess the efficacy and safety of the procedure in this retrospective study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05739487
Study type	Observational
Source	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Completed
Phase
Start date	July 1, 2020
Completion date	March 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Recruiting	`NCT04526951` - TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)	Phase 3
Recruiting	`NCT04965038` - Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion	Phase 3
Recruiting	`NCT01348633` - Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye	N/A
Completed	`NCT03197194` - A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion	Phase 3
Recruiting	`NCT05562284` - Safety and Efficacy After Selective Intra-arterial Thrombolysis for Central Retinal Artery Occlusion	N/A
Completed	`NCT03049514` - Study of Arterial Recanalization of the Central Retinal Artery Occlusions
Recruiting	`NCT00802698` - The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform	Phase 1/Phase 2
Recruiting	`NCT06178055` - A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arthritic Central Retinal Artery Occlusion (CRAO)	Phase 2